MedTrace Logo

Pharmacokinetic Study of Multiple Doses of ORM-12741 (Nebula PK 2)

NCT02303860 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2015-05-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate ORM-12741 concentrations in blood at steady state.

Conditions

  • Healthy

Interventions

DRUG

ORM-12741 MR A

Modified release formulation of ORM-12741

DRUG

ORM-12741 MR B

Modified release formulation of ORM-12741

DRUG

ORM-12741 IR

Immediately release formulation of ORM-12741

Sponsors & Collaborators

  • Orion Corporation, Orion Pharma

    lead INDUSTRY

Principal Investigators

  • Mika Scheinin, MD · Clinical Research Services Turku - CRST Oy

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02303860 on ClinicalTrials.gov